We further evaluated CleTAC CAR-T cells in an additional solid tumor model—the HER2+ MDA-MB-231 breast carcinoma xenograft—and observed superior tumor control compared with constitutive CAR-T treatment (Figure S9), reinforcing the enhanced efficacy of the CleTAC approach. This evidence concerns the gene ERBB2 and neoplasm.